Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease

EAST HANOVER, N.J., Dec. 8, 2018 /PRNewswire/ -- Novartis today announced data from subgroup analyses of the three pivotal Phase III MONALEESA trials showing that Kisqali® (ribociclib) plus endocrine therapy extended progression-free survival (PFS) compared to endocrine therapy alone,...